ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2024

YTHDF2 Is a Therapeutic Target for HCC by Suppressing Immune Evasion and Angiogenesis Through ETV5/PD-L1/VEGFA Axis.

Jingyuan Wen et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.